There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on AlloVir (ALVR – Research Report), Jazz Pharmaceuticals (JAZZ – Research Report) and Seagen (SGEN – Research Report) with bullish sentiments.
Leerink Partners analyst Mani Foroohar maintained a Buy rating on AlloVir yesterday. The company’s shares closed last Tuesday at $11.20.
According to TipRanks.com, Foroohar has 0 stars on 0-5 stars ranking scale with an average return of
Currently, the analyst consensus on AlloVir is a Strong Buy with an average price target of $42.00.
Jazz Pharmaceuticals (JAZZ)
Leerink Partners analyst Marc Goodman reiterated a Buy rating on Jazz Pharmaceuticals yesterday. The company’s shares closed last Tuesday at $150.02.
According to TipRanks.com, Goodman is a 1-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Jazz Pharmaceuticals with a $202.25 average price target, a 36.6% upside from current levels. In a report released today, BMO Capital also reiterated a Buy rating on the stock with a $202.00 price target.
In a report released yesterday, Andrew Berens from Leerink Partners maintained a Buy rating on Seagen. The company’s shares closed last Tuesday at $145.70.
According to TipRanks.com, Berens has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Seagen has an analyst consensus of Moderate Buy, with a price target consensus of $191.73, representing a 31.1% upside. In a report issued on January 3, William Blair also maintained a Buy rating on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ALVR: